Effect of Dapagliflozin in patients with type 2 daibetes mellitus

Effect of Dapagliflozin in patients with type 2 daibetes mellitus - Effect of Dapagliflozin in patients with type 2 daibetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014922

Enrollment

Registered

2014-08-23

Start date

2014-08-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

Dapagliflozin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes with HbA1c =/> 6.5%

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes 2. Patients with severe renal failure or liver dysfunction 3. Patients with drug allergy for ipraglifrozin 4. Patients with history of diabetec ketosis 5. Patients with shick day

Design outcomes

Primary

Measure	Time frame
The predictive parameters for the effect on Dapaglyflozin	—

Countries

Japan

Contacts

Public ContactTomoyuki Iwasaki

Iwasaki Naika Clinic Endocrinology and Metabolism

toiwasaki-dm@umin.ac.jp045-442-6475

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026